Fast skeletal muscle troponin activator in the dy2J muscular dystrophy model

Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis

(2012) Jeremy Shefner et al.   Amyotrophic Lateral Sclerosis

A call for transparent reporting to optimize the predictive value of preclinical research

(2012) Story C. Landis et al.   NATURE

Raise standards for preclinical cancer research

(2012) C. Glenn Begley et al.   NATURE

Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases

(2012) Alan J Russell et al.   NATURE MEDICINE

Losartan, a therapeutic candidate in congenital muscular dystrophy: Studies in the dy2J/dy2J Mouse

(2011) Moran Elbaz et al.   ANNALS OF NEUROLOGY

Losartan Decreases Cardiac Muscle Fibrosis and Improves Cardiac Function in Dystrophin-Deficient Mdx Mice

(2011) Christopher F. Spurney et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Believe it or not: how much can we rely on published data on potential drug targets?

(2011) Florian Prinz et al.   NATURE REVIEWS DRUG DISCOVERY

The Ras Antagonist, Farnesylthiosalicylic Acid (FTS), Decreases Fibrosis and Improves Muscle Strength in dy2J/dy2J Mouse Model of Muscular Dystrophy

(2011) Yoram Nevo et al.   PLoS One

Hindlimb skeletal muscle function in myostatin-deficient mice

(2010) Bettina A. Gentry et al.   MUSCLE & NERVE

Improved muscle strength and mobility in the dy2J/dy2J mouse with merosin deficient congenital muscular dystrophy treated with Glatiramer acetate

(2010) Oshrat Dadush et al.   NEUROMUSCULAR DISORDERS

Genotype–phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations

(2010) Fatemeh Geranmayeh et al.   NEUROMUSCULAR DISORDERS

Cellular and molecular events controlling skeletal muscle mass in response to altered use

(2008) François B. Favier et al.   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY